|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:abstractText |
The clinical outcome of acid-related disorders treated by proton pump inhibitors (PPIs) might be dependent on the polymorphically expressed cytochrome P450 (CYP) 2C19, which is involved in PPI metabolism. We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-Pyridinylmethylsulfinylbenzimidazo...,
http://linkedlifedata.com/resource/pubmed/chemical/5-hydroxymethylomeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/H( )-K( )-Exchanging ATPase,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/omeprazole sulfone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
627-34
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16338278-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:16338278-Administration, Oral,
pubmed-meshheading:16338278-Adult,
pubmed-meshheading:16338278-Aged,
pubmed-meshheading:16338278-Area Under Curve,
pubmed-meshheading:16338278-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:16338278-Case-Control Studies,
pubmed-meshheading:16338278-Cytochrome P-450 CYP3A,
pubmed-meshheading:16338278-Cytochrome P-450 Enzyme System,
pubmed-meshheading:16338278-Enzyme Inhibitors,
pubmed-meshheading:16338278-Female,
pubmed-meshheading:16338278-Gastroesophageal Reflux,
pubmed-meshheading:16338278-Genotype,
pubmed-meshheading:16338278-H(+)-K(+)-Exchanging ATPase,
pubmed-meshheading:16338278-Half-Life,
pubmed-meshheading:16338278-Humans,
pubmed-meshheading:16338278-Male,
pubmed-meshheading:16338278-Middle Aged,
pubmed-meshheading:16338278-Mixed Function Oxygenases,
pubmed-meshheading:16338278-Omeprazole,
pubmed-meshheading:16338278-Prospective Studies,
pubmed-meshheading:16338278-Time Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
|
|
pubmed:affiliation |
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. mattias.schwab@stjude.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
